ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,424.20
0.05%
Dow Jones
39,806.77
-0.49%
Gold vs US Dollar
2,419.845
-0.27%
Brent Oil
83.21
-0.38%
Bitcoin
70,996.19
-0.63%
Pepperstone
Advertisement
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Molecular Partners AG (MOLN)

  7. Molecular Partners AG (MOLN) News

Molecular Partners (MOLN)

Molecular Partners AG
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:MOLN
DateTimeSourceHeadlineSymbolCompany
17/05/202411:25Edgar (US Regulatory)Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]NASDAQ:MOLNMolecular Partners AG
17/05/202411:25Edgar (US Regulatory)Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]NASDAQ:MOLNMolecular Partners AG
17/05/202411:25Edgar (US Regulatory)Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]NASDAQ:MOLNMolecular Partners AG
17/05/202411:25Edgar (US Regulatory)Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]NASDAQ:MOLNMolecular Partners AG
16/05/202421:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MOLNMolecular Partners AG
16/05/202421:00GlobeNewswire Inc.Interim Management Statement Q1 2024 of Molecular Partners: Pipeline Progressing with Two Additional Programs to Enter the Clinic in 2025, Update to MP0533 ProgramNASDAQ:MOLNMolecular Partners AG
29/04/202416:00GlobeNewswire Inc.Molecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533’s Proposed Mechanism of Action NASDAQ:MOLNMolecular Partners AG
19/04/202416:12GlobeNewswire Inc.Life Science Cares Launches in SwitzerlandNASDAQ:MOLNMolecular Partners AG
17/04/202416:12GlobeNewswire Inc.Molecular Partners Announces All Board Proposals Approved at the Annual General MeetingNASDAQ:MOLNMolecular Partners AG
26/03/202413:26GlobeNewswire Inc.Molecular Partners Publishes Invitation to Annual General Meeting 2024NASDAQ:MOLNMolecular Partners AG
14/03/202420:00GlobeNewswire Inc.Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023NASDAQ:MOLNMolecular Partners AG
01/03/202421:00GlobeNewswire Inc.Molecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor PresentationsNASDAQ:MOLNMolecular Partners AG
08/01/202417:33Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MOLNMolecular Partners AG
07/01/202421:00GlobeNewswire Inc.Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:MOLNMolecular Partners AG
05/01/202421:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MOLNMolecular Partners AG
05/01/202421:00GlobeNewswire Inc.Molecular Partners and Orano Med Announce Co-Development Agreement for Radio-DARPin TherapiesNASDAQ:MOLNMolecular Partners AG
14/12/202306:00GlobeNewswire Inc.Molecular Partners to Present at 42nd Annual J.P. Morgan Healthcare Conference and Swiss Investor ConferencesNASDAQ:MOLNMolecular Partners AG
10/12/202317:00GlobeNewswire Inc.Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual MeetingNASDAQ:MOLNMolecular Partners AG
14/11/202306:00GlobeNewswire Inc.Molecular Partners to Present on DARPin Oncology Innovations at Protein & Antibody Engineering Summit Europe (PEGS)NASDAQ:MOLNMolecular Partners AG
03/11/202316:00GlobeNewswire Inc.Molecular Partners Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual MeetingNASDAQ:MOLNMolecular Partners AG
02/11/202310:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MOLNMolecular Partners AG
02/11/202306:00GlobeNewswire Inc.Molecular Partners to Present Initial Data from Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at the 65th ASH Annual Meeting and ExpositionNASDAQ:MOLNMolecular Partners AG
01/11/202306:00GlobeNewswire Inc.Molecular Partners to Participate in the TD Cowen 7th Annual Fall Oncology Innovation SummitNASDAQ:MOLNMolecular Partners AG
26/10/202321:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MOLNMolecular Partners AG
26/10/202321:00GlobeNewswire Inc.Molecular Partners Interim Management Statement Q3 2023: Continued Validation Seen Across the DARPin PortfolioNASDAQ:MOLNMolecular Partners AG
13/09/202306:00GlobeNewswire Inc.Molecular Partners Presents New Data on its Radio DARPin Therapy (RDT) Platform at the EANM 2023 Annual MeetingNASDAQ:MOLNMolecular Partners AG
24/08/202321:02Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MOLNMolecular Partners AG
24/08/202321:00GlobeNewswire Inc.Molecular Partners Reports H1 2023 Corporate Highlights and FinancialsNASDAQ:MOLNMolecular Partners AG
28/06/202313:35Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:MOLNMolecular Partners AG
28/06/202313:34Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:MOLNMolecular Partners AG
 Showing the most relevant articles for your search:NASDAQ:MOLN

Your Recent History

LSE
ENET
Ethernity Networks
LSE
VAL
Valirx
LSE
ARCM
Arc Minerals
LSE
GLEN
Glencore
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved